




Validation Data




Recombinant Human Noggin/NOG Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.




Immobilized recombinant Human BMP2 at 1 $\mu\text{g/mL}$ (100 $\mu\text{L/well}$) can bind Noggin with a linear range of 2-57 ng/mL.




Immobilized recombinant Human BMP4 at 0.5 $\mu\text{g/mL}$ (100 $\mu\text{L/well}$) can bind Noggin with a linear range of 4-47 ng/mL.




Immobilized Human Noggin at 1 $\mu\text{g/mL}$ (100 $\mu\text{L/well}$) can bind Noggin Rabbit pAb with a linear range of 1-3.5 ng/mL.




Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED_{50} for this effect is 13.28-53.12 ng/mL in the presence of 50 ng/mL of recombinant human BMP-4, corresponding to a specific activity of 1.88×10^4 - 7.53×10^4 units/mg.




Human stomach organoids were cultured with EGF(Cat. RP03287), FGF10(Cat. RP01140), NOG(Cat. RP01237), RSPO1(Cat. RP00071), WNT-3a(Cat. RP01618SLQ).



Mouse large intestinal organoids were cultured with EGF(Cat. RP03287), NOG(Cat. RP01237), RSPO1(Cat. RP00071), WNT-3a(Cat. RP01618SLQ).




Mouse small intestinal organoids were cultured with EGF(Cat. RP03287), NOG(Cat. RP01237), RSPO1(Cat. RP00071).




Human liver organoids were cultured with EGF(Cat. RP03287), HGF(Cat. RP01602), FGF2(Cat. RP01042), FGF10(Cat. RP01140), NOG(Cat. RP01237), RSPO1(Cat. RP00071), WNT-3a(Cat. RP01618SLQ).


Validation Data




Human kidney organoids were cultured with EGF(Cat. RP03287), FGF2(Cat. RP01042), FGF7(Cat. RP01717), FGF9(Cat. RP01710), FGF10(Cat. RP01140), IGF-(Cat. RP00996), NOG(Cat. RP01237), RSPO1(Cat. RP00071), WNT-3a(Cat. RP01618SLQ). And further, DKK-1(RP01343) was used to induce the establishment of cell polarity.



Human colorectal cancer organoid were cultured with EGF(Cat. RP03287), NOG(Cat. RP01237) FGF10(Cat. RP01140), RSPO1(Cat. RP00071), HGF(Cat. RP01602), A83-01(Cat. RPM0008), SB202190(Cat. RPM0010), Y-27632 dihydrochloride(Cat. RPM0007), Acetylcysteine/NAC(Cat. RPM0017), Nicotinamide (Cat. RPM0016), Gastrin I(Cat. RPM0011), AB-27 Supplement(Cat. RPM0047LQ), N-2 Supplement(Cat. RPM0047LQ).



Human gastric cancer organoid were cultured with EGF(Cat. RP03287), NOG(Cat. RP01237), FGF10(Cat. RP01140), RSPO1(Cat. RP00071), Wnt-3a Surrogate(Cat. RP01618SLQ), A83-01(Cat. RPM0008), Y-27632 dihydrochloride(Cat. RPM0007), Gastrin I(Cat. RPM0011), AB-27 Supplement(Cat. RPM0047LQ), N-2 Supplement(Cat. RPM0046LQ).



Mouse lung organoids were cultured in Matrigel (Cat. RPM0003) with medium supplemented with EGF (Cat. RP03287), Noggin (Cat. RP01237), RSPO1 (Cat. RP00071), Wnt-3a (Cat. RP01618SLQ), and FGF-10 (Cat. RP01140). After 8 days of culture, the expression of lineage markers, including E-Cadherin (Cat. A20798), AQP5 (Cat. A23292), and CD49F (Cat. A26707), was assessed by ultra-plex immunofluorescence staining.